Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Peters KB, Affronti ML, Woodring S, Lipp E, Healy P, Herndon JE 2nd, Miller ES, Freeman MW, Randazzo DM, Desjardins A, Friedman HS. Peters KB, et al. Among authors: desjardins a. Support Care Cancer. 2022 Apr;30(4):3463-3471. doi: 10.1007/s00520-021-06738-0. Epub 2022 Jan 10. Support Care Cancer. 2022. PMID: 35001215 Clinical Trial.
Chemotherapy and novel therapeutic approaches in malignant glioma.
Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Desjardins A, et al. Front Biosci. 2005 Sep 1;10:2645-68. doi: 10.2741/1727. Front Biosci. 2005. PMID: 15970525 Review.
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: desjardins a. Cancer. 2005 Oct 1;104(7):1478-86. doi: 10.1002/cncr.21316. Cancer. 2005. PMID: 16088964 Free article. Clinical Trial.
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Quinn JA, et al. Among authors: desjardins a. J Clin Oncol. 2005 Oct 1;23(28):7178-87. doi: 10.1200/JCO.2005.06.502. J Clin Oncol. 2005. PMID: 16192602 Clinical Trial.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. Among authors: desjardins a. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial.
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: desjardins a. J Clin Oncol. 2006 Jan 1;24(1):115-22. doi: 10.1200/JCO.2005.03.4082. J Clin Oncol. 2006. PMID: 16382120 Clinical Trial.
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Reardon DA, et al. Among authors: desjardins a. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8. doi: 10.1158/1078-0432.CCR-05-2215. Clin Cancer Res. 2006. PMID: 16467100 Clinical Trial.
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Reardon DA, et al. Among authors: desjardins a. J Nucl Med. 2006 Jun;47(6):912-8. J Nucl Med. 2006. PMID: 16741299 Free article. Clinical Trial.
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ. Badruddoja MA, et al. Among authors: desjardins a. Neuro Oncol. 2007 Jan;9(1):70-4. doi: 10.1215/15228517-2006-022. Epub 2006 Nov 15. Neuro Oncol. 2007. PMID: 17108065 Free PMC article. Clinical Trial.
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Desjardins A, et al. J Neurooncol. 2007 May;83(1):53-60. doi: 10.1007/s11060-006-9302-2. Epub 2007 Jan 24. J Neurooncol. 2007. PMID: 17245623 Clinical Trial.
378 results